Research programme: caspase-8 inhibitors - Apoxis
Latest Information Update: 28 Jun 2004
At a glance
- Originator Apoxis
- Mechanism of Action Caspase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Allotransplant rejection
Most Recent Events
- 28 Jun 2004 Discontinued - Preclinical for Allotransplant rejection in Switzerland (unspecified route)
- 02 Jul 2003 Preclinical trials in Allotransplant rejection in Switzerland (unspecified route)